The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, ...

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

As the NMPA joins the EU and the U.S. in placing sterility assurance and contamination control front and center, ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...